We serve Chemical Name:1,1-bis(2-hydroxyethyl)-3-octadecylurea CAS:36837-80-6 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:1,1-bis(2-hydroxyethyl)-3-octadecylurea
CAS.NO:36837-80-6
Synonyms:N,N-Bis(2-hydroxyethyl)-N’-stearylurea;EINECS 253-233-7
Molecular Formula:C23H48N2O3
Molecular Weight:400.63900
HS Code:
Physical and Chemical Properties:
Melting point:N/A
Boiling point:578.9ºC at 760mmHg
Density:0.962g/cm3
Index of Refraction:1.483
PSA:76.29000
Exact Mass:400.36600
LogP:5.44850
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like N,N-Bis(2-hydroxyethyl)-N’-stearylurea chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,EINECS 253-233-7 physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,EINECS 253-233-7 Use and application,EINECS 253-233-7 technical grade,usp/ep/jp grade.
Related News: SARS-CoV-2 has evolved mutations that severely compromise the neutralizing activities of multiple IgG monoclonal antibodies, including those under clinical trials and authorized for emergency use.
Therefore, developing new antibody therapies that can overcome these challenges is an urgent unmet need, and we are pleased with the data published today,” An said.
“Synergizing the strengths of multiple institutions from academia and industry is the key to the rapid translation from ideas to therapeutic candidates.
This is another example of such success. The cross-institutional and academic-industry collaborations should be expanded to other disease indications,” said Pei-Yong Shi, PhD, professor and co-senior author of the study from the Department of Biochemistry and Molecular Biology at UTMB Health.
This antibody has been licensed to biotech partner IGM Biosciences for drug development.
“The ability to use potently neutralizing IgM antibodies against SARS-CoV-2 with broad coverage of VOCs, VOIs, and viral escape mutants, is a very exciting application of the IGM platform,” said Fred Schwarzer, CEO of IGM Biosciences.
“We are grateful to our collaborators at UTHealth, UTMB Health, and our scientists at IGM for the exceptional work described in Nature today. N-(2-fluorophenyl)-2-{[1-(1-naphthyl)-1H-tetrazol-5-yl]thio}acetamide manufacturers Competition is indeed “severe” from local firms, Wang said, but the company is working to add new drugs and indications to the market and is noticing increased volumes from national reimbursement deals. 4-chloro-N-(2-(2-(2-(2-methoxyphenyl)-5-methyl-4-oxothiazolidin-3-yl)thiazol-4-yl)phenyl)benzenesulfonamide suppliers Case in point: Hansoh Pharma is seeking approvals for its third-generation EGFR inhibitor Ameile (almonertinib) for newly diagnosed EGFR-mutated non-small cell lung cancer. 4,4′-(r-2,t-4-Bis(4-nitrophenyl)-1,3-cyclobutandiyliden)bis(2,6-di-tert-butyl-4H-pyran) vendor & factory.
Therefore, developing new antibody therapies that can overcome these challenges is an urgent unmet need, and we are pleased with the data published today,” An said.
“Synergizing the strengths of multiple institutions from academia and industry is the key to the rapid translation from ideas to therapeutic candidates.
This is another example of such success. The cross-institutional and academic-industry collaborations should be expanded to other disease indications,” said Pei-Yong Shi, PhD, professor and co-senior author of the study from the Department of Biochemistry and Molecular Biology at UTMB Health.
This antibody has been licensed to biotech partner IGM Biosciences for drug development.
“The ability to use potently neutralizing IgM antibodies against SARS-CoV-2 with broad coverage of VOCs, VOIs, and viral escape mutants, is a very exciting application of the IGM platform,” said Fred Schwarzer, CEO of IGM Biosciences.
“We are grateful to our collaborators at UTHealth, UTMB Health, and our scientists at IGM for the exceptional work described in Nature today. N-(2-fluorophenyl)-2-{[1-(1-naphthyl)-1H-tetrazol-5-yl]thio}acetamide manufacturers Competition is indeed “severe” from local firms, Wang said, but the company is working to add new drugs and indications to the market and is noticing increased volumes from national reimbursement deals. 4-chloro-N-(2-(2-(2-(2-methoxyphenyl)-5-methyl-4-oxothiazolidin-3-yl)thiazol-4-yl)phenyl)benzenesulfonamide suppliers Case in point: Hansoh Pharma is seeking approvals for its third-generation EGFR inhibitor Ameile (almonertinib) for newly diagnosed EGFR-mutated non-small cell lung cancer. 4,4′-(r-2,t-4-Bis(4-nitrophenyl)-1,3-cyclobutandiyliden)bis(2,6-di-tert-butyl-4H-pyran) vendor & factory.
